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Background: A novel herbal formulation LI10903F, alternatively known as LOWAT was developed based on its
ability to inhibit adipogenesis and lipogenesis in 3T3-L1 adipocytes model. The clinical efficacy and tolerability of
LI10903F were evaluated in an eight-week, randomized, double-blind, placebo-controlled, clinical trial in 50 human
subjects with body mass index (BMI) between 30 and 40 kg/m2 (clinical trial registration number: ISRCTN37381706).
Participants were randomly assigned to either a placebo or LI10903F group. Subjects in the LI10903F group
received 300 mg of herbal formulation thrice daily, while subjects in the placebo group received 300 mg of
placebo capsules thrice daily. All subjects were provided a standard diet (2,000 kcal daily) and participated in a
moderate exercise of 30 min walk for five days a week. Additionally, the safety of this herbal formulation was
evaluated by a series of acute, sub-acute toxicity and genotoxicity studies in animals and cellular models.
Results: After eight weeks of supplementation, statistically significant net reductions in body weight (2.49 kg;
p=0.00005) and BMI (0.96 kg/m2; p=0.00004) were observed in the LI10903F group versus placebo group.
Additionally, significant increase in serum adiponectin concentration (p=0.0076) and significant decrease in serum
ghrelin concentration (p=0.0066) were found in LI10903F group compared to placebo group. Adverse events were
mild and were equally distributed between the two groups. Interestingly, LI10903F showed broad spectrum safety
in a series of acute, sub-acute toxicity and genotoxicity studies.
Conclusions: Results from the current research suggest that LI10903F or LOWAT is well-tolerated, safe and effective
for weight management.
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Studies indicate that obesity-related risk factors are pre-
ventable and even ameliorable through weight loss and
long-term weight management programs [1-3]. There are
three major weight management strategies: 1) life style
intervention such as diet and exercise as well as dietary
supplements, 2) pharmacotherapy, and 3) bariatric surgery
for morbidly obese subjects. While pharmacotherapy may
be effective, it also has significant adverse effects and limi-
tations [4]. Since obesity is associated with an imbalance
between food intake and energy expenditure, a long-term* Correspondence: krishanu@lailanutra.com
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reproduction in any medium, provided the orlifestyle change including healthy diet and exercise in con-
junction with effective weight management supplements
may present a cost-effective intervention for obesity [5-8].
In fact, informed consumers are increasingly seeking die-
tary supplements which have been shown to be efficacious
and safe in promoting weight loss [9].
In order to develop an effective and safe weight loss in-
gredient, we screened extracts of more than four hundred
medicinal plants for their ability to inhibit adipogenesis in
3T3-L1 mouse adipocytes. Among the candidate plant
extracts tested, Piper betle leaf extract and Dolichos
biflorus seed extract showed potent anti-adipogenic effi-
cacy. These two extracts were selected for further studies
by combining individual extracts at different ratios. Aral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Sengupta et al. Lipids in Health and Disease 2012, 11:176 Page 2 of 9
http://www.lipidworld.com/content/11/1/176combination of P. betle leaf extract and D. biflorus seed
extract in a ratio of 2:3, LI10903F also known as LOWAT
demonstrated greater anti-adipogenic as well as lipolytic
activities compared to the individual extracts.
Here we report the in vitro development of LI10903F or
LOWAT and the results of its safety studies. In addition,
we present the findings of a randomized, double-blind,
placebo-controlled clinical study demonstrating the tole-





The dried plant material (1kg) of Piper Betle leaves was
pulverized to course powder and extracted with 60%
alcohol at 70°C for 2h. The extraction process was
repeated with the residue for three times. The extracts
were combined, filtered and evaporated under reduced
pressure at 50-60°C to obtain a residue (120g).
Dolichos biflorus
The dried seeds (1kg) of Dolichos biflorus were pulverized
to course powder and extracted with 90% alcohol for 1h.
The extract was filtered and the residue was subjected for
repeated extraction for 3 times. The extracts were com-
bined and evaporated under vacuum to obtain a residue
(100g). LI10903F is a 2:3 combination of P. betle leaf
aqueous-alcohol extract and D. biflorus seed alcohol
extract.
Chemicals and reagents
Isopropyl alcohol, insulin, dexamethasone, 3-isobutyl-1-
methylxanthine (IBMX), Oil red O, Dulbecco’s modified
Eagle’s medium (DMEM), glutamine, glucose, penicillin,
streptomycin were obtained from Sigma Chemical Co.
(St. Louis, MO). Fetal bovine serum (FBS) was pur-
chased from Hyclone (Logan, UT). All other reagents
were purchased from Sigma Chemical Co. unless other-
wise indicated.
In vitro studies
Cell culture and treatment
Mouse pre-adipocyte fibroblasts 3T3-L1 cells were
obtained from American Type Culture Collection
(Manassas, VA) and cultivated in maintenance me-
dium comprised of DMEM supplemented with 10%
FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 1
mM sodium pyruvate and 4.5 g/L D-glucose.
Adipogenesis assay
Equal number of 3T3-L1 cells (60,000 cells per well) was
seeded in each well of 24-well culture plates. Cells were
pre-treated with different concentrations of herbal extractsor formulations for 2h and incubated further with the di-
fferentiation medium containing 500 nM insulin, 1 μM
dexamethasone, and 0.5 mM IBMX for 48h. Thereafter,
cells were maintained in the post-differentiation medium
(DMEM containing 100nM insulin) in presence or ab-
sence of LI10903F for further 8 days. The control cultures
received only 0.1% (v/v) DMSO as the vehicle. The intra-
cellular lipid accumulation was measured by staining the
cells with Oil Red O stain following the method described
earlier [10].
Lipolysis assay
The intracellular lipid breakdown efficacy of herbal
extracts and their formulations was evaluated by mea-
suring the released glycerol in the 3T3-L1 culture super-
natants. Equal number of mature adipocytes was treated
with different concentrations of either P. Betle or D.
biflorus extracts or their formulations in phenol red-free
DMEM supplemented with 2% bovine serum albumin
(BSA) for 4h. Released glycerol in the cell free culture
supernatants was measured using the Adipolysis Assay Kit
(Millipore, Billerica, MA) as described previously [10].
Toxicity studies
Acute oral and 28-day dose-dependent oral toxicity
studies were conducted at Laila Impex R&D Centre
(Vijayawada, India). In vitro chromosome aberration
test and mammalian erythrocyte micronucleus test
were conducted at Shriram Institute for Industrial Re-
search (Delhi, India). Ames bacterial reverse mutation
assay was conducted at Vimta Labs Limited (Hyderabad,
India). All studies complied with the Good Laboratory
Practice (GLP) Standards, and were done according to
the OECD guidelines for the testing of chemicals. The
details of these procedures were described previously by
Sreejayan et al. [11].
Acute oral toxicity
An acute oral toxicity study was conducted following the
protocol as described earlier [11]. Three Sprague–Dawley
(SD) female rats, nulliparous and non-pregnant (age: 12
weeks; 205–230 g body weight at study initiation) were
administered orally with a single dose of 5000 mg/kg of
LI10903F. All the animals were observed for mortality,
signs of gross toxicity, and behavioral changes on the day
of dosing and thereafter for 14 days. All animals were
euthanized using anesthetic ether at the end of the obser-
vation period and subjected to necropsy.
28-day sub-chronic toxicity
A twenty-eight day sub chronic toxicity study was con-
ducted following the protocol as described earlier [12].
Forty healthy Sprague Dawley rats (20 males and 20
females) were equally divided into four groups. Each
Sengupta et al. Lipids in Health and Disease 2012, 11:176 Page 3 of 9
http://www.lipidworld.com/content/11/1/176group of animals (n=10) was supplemented with 50 or
250 or 2500 mg/kg LI10903F or vehicle (1% CMC). The
animals were given LI10903F for 28 consecutive days by
oral gavage using a ball-tipped gavage needle attached to
an appropriate syringe. Animals were monitored for
mortality, toxicity, and behavioral changes throughout
the study period. Body weights were recorded before
dosing (Day 0), and at weekly intervals thereafter.Ames test: reverse mutation assay
The reverse mutation test measures the ability of
LI10903F to induce reverse mutation at selected histidine
loci in five tester strains of Salmonella typhimurium TA
98, TA 100, TA 102, TA 1535, and TA 1537 (Molecular
Toxicology, Boone, NC). In the dose-range finding study,
the herbal blend was tested at the dose levels of 39.06,
78.13, 156.25, 312.50, 625, 1250, 2500, and 5000μg/mL in
presence (10% S9 fraction v/v) or absence of metabolic
activation system.Mammalian erythrocyte micronucleus test
A total of 60 healthy Swiss albino mice (30 males, 30
females) of approximately 8–12 weeks age were ran-
domly assigned to three main study groups (n=20) with
equal number of either gender of animals in each group.
Animals in Group 1 were administered orally with 2000
mg/kg of LI10903F; animals in Group 2 and Group 3
were administered with corn oil (negative control) and
40 mg/kg cyclophosphamide via i.p., respectively. Ani-
mals were observed for toxicity or mortality. Five males
and five females from each group were sacrificed after
24h, and similarly five males and five females after 48h
of dose administration. The bone marrow smears were
prepared from femur, stained with May and Graunwald
stain and examined for polychromatic erythrocytes
(PCE) under 40X objective of a Nikon Eclipse TS 100
microscope (Nikon Corporation, Japan).Mammalian chromosome aberration test
Whole blood was collected in heparinized vial from two
healthy male human volunteers. The test was conducted
on isolated lymphocytes at 1000, 2500 and 5000 μg/mL of
LI10903F with or without metabolic activation. Cultures
treated with mitomycin-C or cyclophosphamide served as
positive control, whereas, culture treated with 0.1%
DMSO as negative control. Colchicine was added to the
cultures 2h prior to harvesting. After 18h of treatment
with LI10903F, lymphocytes were harvested for assessing
chromosomal aberration. Metaphase preparations were
stained with Giemsa and aberrations classified and scored
under 40X objective of a Nikon Eclipse TS 100 micro-
scope (Nikon Corporation, Japan).Clinical study material
The study material LI10903F or LOWAT is a blend of
60% alcohol extract of P. bettle leaves standardized to
6% polyphenols plus 90% alcohol extract of D. biflorus
seeds standardized to 4% γ-glutamyl phenylalanine
mixed in 2:3 ratio. For clinical study, three hundred
milligrams of LI10903F was encapsulated in opaque cap-
sules with 200 mg of exicipient. A combination of micro
crystalline cellulose and Magnesium stearate (<2%) was
used as the excipient. Placebo capsules contained only
exicipient, and were identical in appearance, size, weight
and color to the active capsules. The formulation was
provided by InterHealth Nutraceuticals (Benicia, CA).
Trial site and recruitment of subjects
This randomized, double-blind, placebo controlled, cli-
nical trial (RCT) was performed at Alluri Sitarama Raju
Academy of Medical Sciences (ASRAM), Eluru, Andhra
Pradesh, India (clinical trial registration number:
ISRCTN37381706). The protocol was evaluated and
approved by the ASRAM Institutional Review Board (IRB).
IRB approval Reference number, 07-001/IB/PHF OB.
One hundred forty five subjects participated in a
questionnaire-based screening process. Inclusion criteria
were: adults (21–50 years), BMI ≥ 30 kg/m2, female par-
ticipants should not be pregnant, willingness to follow
method of birth control if premenopausal. Exclusion cri-
teria were: morbidly obese (BMI > 40 kg/m2), history of
thyroid disease, cardiovascular disease, diabetes, hepa-
titis, pancreatitis, lactic acidosis or hepatomegaly with
steatosis, motor weakness, peripheral sensory neuro-
pathy; allergies to spices and herbal products; using
weight loss medications, laxatives or diuretics taken
solely for the purpose of weight loss; recent unexplained
weight loss or gain; HIV positive; any evidence of organ
dysfunction or any clinically significant deviation from
normal that could impact subjects well-being or clin-
ical outcome. Of 145 candidates screened 50 subjects
who met eligibility criteria were enrolled in the study.
Each participant voluntarily signed the IRB-approved,
informed-consent form. At baseline visit, the subjects
were randomized into either the placebo or LI10903F
group.
Study design
At baseline visit, all subjects were provided with
LI10903F or placebo capsules, compliance cards, and
dates for follow-up evaluations. A standard diet (2,000
kcal daily) was provided (breakfast, lunch and dinner)
deriving 61% kcal from carbohydrate, 14% from protein
and 25% from fat. The subjects were required to walk 30
min, five days a week under the supervision of a physical
trainer. The subjects were instructed to take 3 capsules a
day, one each 30 min before breakfast, lunch and dinner.
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at baseline and compliance reports during follow-up
evaluations at 14, 28 and 56 days. Subjects were assessed
for body weight, height, waist plus hip circumference
and vital signs at baseline and subsequent follow-up vi-
sits. At all study visits, blood samples were collected for
hematological and biochemical evaluations, and urine
samples for urinalysis. Reduction in body weight and
BMI were considered as the primary study outcome
parameters of the study. Sample size calculations were
done using power analysis based on previous obesity
study report [13]. We estimated that more than 95%
power at the two-tailed α level of 0.05 would be pro-
vided to test the significance of weight reduction over
placebo with 25 subjects per group.Serum adipokine assay
Serum adiponectin and ghrelin levels were determined
using the human Adiponectin ELISA kit (Millipore, St.
Charles, MO) and the human Ghrelin ELISA kit (Millipore,
St. Charles, MO). The detection sensitivity of adiponec-
tin and ghrelin assays was 0.78 ng/ml and 8 pg/ml,
respectively.Statistical analysis
Mean values were compared with analysis of variance
(ANOVA) on variables for between-group differences at
each individual time point with repeated measurements
using group and time as main effects and baseline of the
variables and gender as covariate. For baseline (week 0)
comparisons, a t-test was used. For inter group compari-
sons, a p-value < 0.05 is considered to be statistically
significant. All comparisons reported are between the
placebo and LI10903F groups at each specified time
point. All analyses were performed with SYSTAT
(Windows version 11.0; San Jose, CA).Table 1 Herbal extracts inhibit adipogenesis in 3T3-L1 cells
Treatments Treatment
conc.
Percent of inhibition in Adipogenesis
1st Assay 2nd Assay 3rd Assay
P. betel 10μg/ml 23.79 20.80 21.28
25μg/ml 27.50 24.85 26.06
50μg/ml 42.98 42.78 41.01
D. biflorus 10μg/ml 26.68 25.98 25.38
25μg/ml 26.56 33.87 30.07
50μg/ml 37.50 40.99 38.97
LI10903F 10μg/ml 27.91 33.76 30.29
25μg/ml 38.52 43.52 40.82
50μg/ml 52.89 58.96 55.54
* Paired t-test, P<0.05 Significant.Results
LI10903F inhibits adipogenesis in 3T3-L1 adipocytes
A panel of Indian herbs indicated for various medicinal
uses in Ayurveda was screened for anti-adipogenesis ac-
tivity following a standard screening protocol [14]. Based
on the ability to inhibit lipid accumulation in 3T3-L1
adipocytes, we selected 60% alcohol extract of P. Betle
leaf and 90% alcohol extract of D. biflorus seeds. Table 1
shows percent inhibition of adipogenesis by these
extracts at 10, 25 and 50 μg/ml. Thereafter, with an in-
tension to develop a synergistic formulation with better
anti-adipogenic properties than the stand alone, these
two extracts were combined at different ratios such as
1:1, 2:1, 1:2, 2:3, 3:2, 1:4, 4:1. Interestingly, we observed
that the formulation composed of 2 parts of P. Betle leaf
extract and 3 parts of D. biflorus seeds extract demon-
strated significantly better anti-adipogenic activity than
the individual extracts (Table 1). Lipid staining in 3T3-L1
adipocytes revealed that LI10903F inhibited adipocyte di-
fferentiation and lipid accumulation in a dose-dependent
manner (Figure 1, A-D). In comparison with the vehicle
(0.1% DMSO) treated cultures, LI10903F treatment exhi-
bited 30.65% (p=0.0079), 40.95% (p=0.0021) and 55.80%
(p=0.0001) inhibition in adipogenesis at 10, 25, 50 μg/mL,
respectively (Figure 1E).LI10903F promotes lipolysis in 3T3-L1 adipocytes
The effect of LI10903F on lipolysis (measured as glycerol
secretion) in matured 3T3-L1 adipocytes showed a dose-
dependent increase compared to the 0.1% DMSO trea-
ted control cultures (Figure 1F). Adipocytes treated with
10, 25 and 50μg/mL LI10903F exhibited 18.10%
(p=0.0123), 28.26% (p=0.0023) and 51.39% (p=0.0003)
increase in glycerol content in culture medium, in com-
parison with the vehicle treated cultures. This observa-
tion indicates that LI10903F increases lipolysis or fat
mobilization from the adipocytes.SD P values*







30.65 3.07 0.0108 0.0562
40.95 2.52 0.0008 0.0134
55.80 3.11 0.0019 0.0012
Figure 1 3T3-L1 cells were induced to differentiate in presence
or absence of different concentrations of LI10903F. Intracellular
Lipids were stained with Oil Red O. Representative
photomicrographs show lipid accumulation in the cells treated with
0.1% DMSO as vehicle control (A); cells treated with 10, 25 and
50μg/ml LI10903F (B, C, and D, respectively). Panel E, bar diagram
represents percent inhibition of adipogenesis (mean ± SD) in
LI10903F treated 3T3-L1 cells relative to the vehicle control cultures
(n=3). Bound Oil Red O dye was eluted from treated adipocytes with
100% isopropyl alcohol, and the OD was read at 550 nm. * Denotes
significantly different compared to control cultures, p<0.05. Panel F,
3T3-L1 adipocytes were treated with either different concentrations
of the herbal blend (10, 25 or 50μg/mL) or 0.1% DMSO (control).
Lipid breakdown was estimated based on the amount of glycerol
released in the culture medium. Bar diagram represents released
glycerol (mean ± SD) in LI10903F treated and vehicle treated
cultures (n=3). *Denotes significantly different compared to vehicle
treated controls, p<0.05.
Table 2 Result summary of toxicity evaluation studies on
LI10903F
Test Result
Acute oral toxicity LD50 > 5,000 mg/kg
28-day sub-acute toxicity NOAEL > 2,500 mg/kg
Ames bacterial assay Non-mutagenic
Mouse micronucleus test Non-mutagenic
Chromosome aberration test Non-mutagenic
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In acute oral toxicity study, administration of the herbal
blend at a limit dose of 5000 mg/kg in female SD rats
did not show any significant abnormalities in all exam-
ined tissues. Based on these results, the oral LD50 of the
herbal blend was concluded to be > 5000 mg/kg body
weight (Table 2).
In 28-day repeat dose toxicity study, oral administration
of LI10903F to male and female SD rats at a dose of 0, 50,
250 or 2500 mg/kg for 28 days did not show any toxico-
logically significant effects. There were no significant ad-
verse effects observed in serum biochemistry, hematology
or microscopic tissue examination (data not shown).
Based on these data, the no-observed-adverse effect-level
(NOAEL) for the herbal blend was considered to be atleast 2500 mg/kg body weight in male and female SD rats
(Table 2).
LI10903F is non-mutagenic and non-genotoxic
In reverse mutation assay, five strains of S. typhimurium
were used to evaluate the mutagenic potential of the
LI10903F in the presence and absence of metabolic activa-
tion. In all doses including the highest dose of 5000 μg/ml,
the mutant frequency was below 1.5. According to
the OECD guidelines, these observations indicate that
LI110903 is non-mutagenic. This herbal formulation did
not affect mitotic index at up to the dose of 5000 μg/ml,
and also failed to induce structural chromosomal damage
in the immature erythrocytes. In addition, micronucleus
test conducted in mammalian erythrocytes demonstrates
that LI10903F is not cytotoxic at the highest dose level at
2000 mg/kg. Table 3 depicts a summary of the cytogenetic
effects of LI10903F at the highest dose levels tested in
Erythrocyte micronucleus test and chromosomal aberra-
tion test, respectively. In summary, these observations to-
gether suggest that LI10903F is safe for consumption and
also non mutagenic and non-genotoxic. The overall
results obtained from various toxicity studies are summar-
ized in Table 2.
LI10903F reduces body weight and BMI in obese subjects
Baseline demographic characteristics of subjects with
respect to gender, age, weight, BMI and height were
similar between the placebo and LI10903F supplemented
groups (Table 4). In comparison with the baseline,
LI10903F group experienced 3.11±0.23 kg and 4.28±0.40
kg reductions of body weight at 4 and 8 weeks, respec-
tively. Whereas, 1.58±0.22 kg and 1.79±0.35 kg body
weight were reduced in placebo group at 4 and 8 weeks,
respectively (Table 5). The net reductions in body weight
in LI10903F group were 1.53 kg and 2.49 kg at 4 and 8
weeks, respectively (Table 5). Similarly, significant de-
crease in BMI (1.19±0.08 and 1.66±0.15 kg/m2 at 4 and
8 weeks, respectively) was observed in LI10903F group
compared to the baseline (Table 5). Placebo group
experienced BMI reductions of 0.63±0.09 and 0.70±0.13
kg/m2 at 4 and 8 weeks, respectively. The significant net
reductions in BMI in LI10903F group were 0.56 and
0.96 kg/m2 at 4 and 8 weeks, respectively (Table 5).
Table 3 Summary of cytogenetic effect of LI10903F in mammalian cells








No. of immature Erythrocytes scored 2000 2000 2000
No. of Micronuclei present in immature
erythrocytes
0.60±0.54 0.80±0.49 45.80±4.44




Mitomycin C 0.2 μg/ml
Mammalian Chromosome
Aberration Test
No. of lymphocytes scored 100 100 100
% Numerical Aberrations 0 1.50±0.71 30.50*±7.78
No. of cells with one structural aberration 0 1.50±0.71 39.00*±5.66
No. of cells with two structural aberrations 0.50±0.71 0.50±0.71 38.00*±4.24
% Mitotic Index 3.65±0.12 2.65±0.21 1.30*±0.14
ANOVA, * Significant (p<0.05).
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LI10903F supplementation for 8 weeks resulted in
15.35% (p=0.0076) higher serum adiponectin concentra-
tion as compared to placebo (Table 6). This finding sug-
gests that the herbal formula LI10903F may influence
reducing the fat store in obese individuals in agreement
with the earlier observation that serum adiponectin is
inversely correlated to percent of body fat [15]. Interest-
ingly, LI10903F supplementation also resulted in 20.85%
(p=0.0066) reduction of serum ghrelin levels than in pla-
cebo after 8 weeks. Ghrelin is a peptide hormone pre-
dominantly produced in stomach and is known to
potently enhance feeding and weight gain [16]. Its reduc-
tion in circulating levels may curb appetite thereby pro-
moting weight loss.Table 5 Reduction of body weight and body mass index















Analyses of various hematologic parameters plus other
markers associated with liver, heart, kidney and meta-
bolic function showed no significant difference between
the placebo and the LI10903F groups (Table 7). No
changes were observed for multiple vital signs that
included systolic and diastolic blood pressure and pulse
rate (Table 7). Triglyceride levels were significantly (p <






Number of females (%) 15 (75) 12 (60) NA
Age (years) 37.15 ± 1.51 39.25 ± 1.35 0.307
Height (meters) 1.60 ± 0.02 1.60 ± 0.02 0.993
Body weight (kg) 84.97 ± 2.80 86.83 ± 2.95 0.650
Body mass index (kg/m2) 33.01 ± 0.73 33.67 ± 0.80 0.546
Values are expressed as mean ± SEM.the placebo (Table 7). This is consistent with improved
lipid profile after weight loss [17].
Some minor adverse events were noted during the
course of the 8-week study period, which include gastric
irritation in two subjects (one from each group), abdo-
minal pain in one placebo subject, back pain in one sub-
ject belongs to LI10903F group, and burning sensation
at rectum in one placebo subject. The subjects who
reported these minor events were distributed evenly
throughout the placebo and active groups.Dropouts
Ten subjects, five from each group, dropped from the
study and were lost to follow-up. None of the drop-outs
were associated to an adverse event. As pre-defined in
the study protocol, drop-outs were excluded from all



























Values represents mean ± SEM. *Significant difference between supplement
and placebo groups.
aNet reduction = Herbal minus placebo.





























Results are presented as Mean ± SEM. *Significant difference between placebo
and LI10903F groups.
†Percent Difference Relative to Placebo = (LI10903F group - Placebo) / Placebo
x 100.
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To develop an efficacious and safe herbal formulation
that promotes healthy weight loss, we screened a series
of extracts derived from ayurvedic medicinal plants for
their anti-adipogenic properties. We found that extracts
from P. bettle leaves and D. biflorus seeds blended in a
ratio of 2:3, and exhibited potent in vitro anti-adipogenic
and lipolysis promoting activities. We then conducted a
series of in vivo and in vitro safety studies that demon-
strated this herbal formulation LI10903F or LOWAT is
safe, non-mutagenic and non-genotoxic with an acute
oral LD50 of > 5,000 mg/kg and NOAEL > 2,500 mg/kg
body weight. Interestingly, LI10903F also passed through
other safety studies conducted for acute dermal toxicity,
primary dermal irritation, and primary eye irritation in
various animal models (unpublished observation). TheseTable 7 Changes in biochemical parameters after 8 weeks







SGOT (U/L) −1.50 ± 3.63 −2.55 ± 6.36 0.397
SGPT (U/L) −7.65 ± 2.65 −11.70 ± 4.65 0.839
Cardiac Function
Systolic BP (mm Hg) −2.40 ± 3.00 −12.53 ± 3.92 0.105
Diastolic BP (mm Hg) −0.70 ± 2.07 −5.05 ± 2.89 0.975
Pulse rate (beats/min) 0.80 ± 1.48 −0.11 ± 1.06 0.786
Metabolic panel
Cholesterol (mg/dL) 12.20 ± 7.47 −1.2 ± 6.83 0.119
Triglycerides (mg/dL) −8.76 ± 17.32 −26.50 ± 30.27 0.041*
LDL (mg/dL) −23.43 ± 7.08 −11.64 ± 13.37 0.155
HDL (mg/dL) −3.04 ± 1.23 1.33 ± 4.44 0.873
Fasting Glucose (mg/dL) −6.20 ± 10.68 −16.15 ± 7.35 0.445
Results are presented as Mean ± SEM. *Statistical significant difference is
between the placebo and the herbal groups.
Abbreviations: SGOT=Serum glutamic oxaloacetic transaminase; SGPT=Serum
glutamic pyruvic transaminase; LDL=Low density lipoproteins; HDL=High
density lipoproteins.findings encouraged and led us to conclude that the
herbal formulation was safe, and can be evaluated for its
weight management efficacy in human clinical trials.
The efficacy and tolerability of this herbal blend was
evaluated in a randomized double blind placebo con-
trolled clinical study in overweight and obese subjects
(clinical trial registration number: ISRCTN37381706).
Our observations from this study are that the herbal
blend, when supplemented together with a standard diet
and moderate daily exercise, promotes a significantly
higher reduction of body weight and BMI than food
management and exercise alone. In the clinical study,
subjects received a 900mg daily dose of either LI10903F
or placebo for 8 weeks. At the end of the study, the
herbal formulation supplemented subjects experienced a
greater reduction in body weight (2.4-fold) and BMI
(2.37-fold) than placebo. This higher net loss of body
weight can be attributed to the herbal blend supplemen-
tation rather than to dietary alteration or moderate exer-
cise. This is because all the subjects followed a standard
calorie diet of 2,000 kcal per day as opposed to being
placed on a hypocaloric diet [18-20]. By taking this ap-
proach, we wanted to mitigate the failure of individuals
to comply with their dietary restrictions [21]. Therefore,
we believe that the results derived from this study are
generally applicable to situations in which individuals
adapt a more healthy living style that includes moderate
exercise and diet control.
We also observed a significant reduction in body
weight and BMI as early as four weeks in herbal supple-
mented group. A significantly higher 3.0-fold reduction
of triglycerides was also observed in the herbal group
versus the placebo at 8 weeks. In addition, it is interes-
ting to observe that the other lipid parameters such
as total cholesterol, LDL and HDL were noticeably im-
proved in the herbal formulation supplemented group in
comparison with the placebo. These improvements are
not statistically significant. We have noticed high stand-
ard error values in placebo and treatment groups; this
might be a possible reason for failure to achieve the sta-
tistically better improvements in such parameters. We
believe that further clinical study with larger group sizes
can definitely address this issue. However, this improve-
ment in blood lipid profile may be a secondary beneficial
effect of weight loss [19].
Previous studies report that adiponectin, an adipokine
hormone predominantly secreted by white adipose tissue
(WAT) plays an important role in pathogenesis of obe-
sity and type II diabetes [22]. Circulating adiponectin
levels are lower in subjects with obesity, diabetes and
cardiovascular diseases than those of healthy control
subjects [23]. At the end of the present study, we found
that the serum adiponectin levels were significantly
higher in subjects supplemented with LI10903F than
Sengupta et al. Lipids in Health and Disease 2012, 11:176 Page 8 of 9
http://www.lipidworld.com/content/11/1/176with placebo. This result provides a mechanistic basis
for the effects of the herbal formulation on body fat me-
tabolism. Interestingly, at the end of the study we also
observed that the serum levels of ghrelin was signifi-
cantly lower in LI10903F supplemented group than in
placebo. Ghrelin is predominantly produced by the
stomach in humans [24], it promotes glucose oxidation
and lipogenesis [25]. Ghrelin is a key hormone involved
in controlling hunger [26] by exerting its appetite stimu-
lating effects [27]. Higher level of circulating ghrelin
level is correlated with increased food intake and adipo-
sity in both animals and humans [25,28]. In agreement
with the previous findings our observation suggests that
LI10903F or LOWAT might exert its weight reducing
effects via regulation of food intake. In addition, our
in vitro experiments also suggest that LI10903F might
reduce body fat by inhibiting the differentiation process
from pre-adipocytes to mature adipocytes and enhancing
fat mobilization from the mature adipocytes.
Overall, we did not observe any major adverse events
from the use of the herbal blend. Only a few minor ad-
verse events were reported and they were evenly distri-
buted between the placebo and the herbal groups. There
was no change in blood markers related to liver, kidney
and heart function, nor did we note any changes in sub-
ject vital signs.
In conclusion, supplementation with the herbal blend
at 900 mg per day resulted in statistically significant
reductions in body weight and BMI that exceeded those
achieved via diet management and moderate exercise
alone. Its significant effect on body weight reduction was
seen starting at week 4. Further, serum adiponectin
levels were significantly higher in herbal group than in
placebo, whereas, serum ghrelin levels were significantly
lower in herbal group than in placebo. Analyses of vari-
ous safety parameters indicate that the herbal blend
appears to be well-tolerated for human consumption.
We conclude that this herbal blend appears to be an ef-
fective ingredient for weight management.
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